Fresenius Kabi has moved to gain a sizeable presence in the fast-growing Indonesian pharmaceutical market by agreeing to form a joint venture with Soho Group, the fourth largest pharmaceutical company in Indonesia, by taking a 51% stake in its PT Ethica Industri Farmasi subsidiary. With the deal, Fresenius Kabi will become the market leader in intravenous generics in the country. Indonesia represents an attractive market for foreign pharmaceutical companies and it is expected to double in value by 2018 as the government implements universal healthcare coverage.